Pyxis Oncology, Inc. (PYXS)

Market Cap	63.13M
Revenue (ttm)	16.15M
Net Income (ttm)	-77.33M
Shares Out	61.59M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,074,582
Open	1.090
Previous Close	1.060
Day's Range	1.015 - 1.155
52-Week Range	0.833 - 5.390
Beta	1.17
Analysts	Strong Buy
Price Target	9.20 (+797.56%)
Earnings Date	May 13, 2025

About PYXS

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 1, 2021
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: PYXS
• Website: https://www.pyxisoncology.com

Analyst Forecast

According to 6 analysts, the average rating for PYXS stock is "Strong Buy." The 12-month stock price forecast is $9.2, which is an increase of 797.56% from the latest price.

Price Target

$9.2

(797.56% upside)

Analyst Consensus: Strong Buy